Name: Argent Biopharma (RGT) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

RGT

Pharmaceuticals, Biotechnology & Life Sciences

Argent Biopharma

Short interest: 0.00%; 0.00 pp 30d; as of 19 Aug 2024
Reported shorts: 1
Shares on issue: 48.406M

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About Argent Biopharma

Argent Biopharma Limited is a European-based pharmaceuticals company that focuses on creating innovative plant-inspired medicines and treatments addressing unmet medical conditions. The firm leverages its unique expertise in extracting and processing natural compounds to produce pharmaceuticals that serve niche, underserved markets. With a strong research and development emphasis, Argent positions itself as a leader in naturally-derived pharmaceutical solutions, aiming to enhance treatment efficacy and patient safety.

Company profile →

Argent Biopharma (ASX:RGT) has 0.00% of its shares on issue reported as short positions as of 19 Aug 2024, or about 1 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. RGT is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads RGT today

Zanger BreakoutNot a candidate
CAN SLIMNot a candidate
Minervini Trend TemplateNot a candidate
Crowded-Short BreakoutNot a candidate
Quality compoundersNot a candidate

Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

RGT fundamentals

In the year to 30 Jun 2026, Argent Biopharma (ASX:RGT) recorded revenue of A$161.2K and a net loss after tax of A$7.7M. A year earlier it recorded revenue of A$583.4K and a net loss after tax of A$17.8M. Year-on-year growth: revenue −72.4% (FY). Net margin −4,783.3% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit) and Yahoo Finance, as at 14 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →